These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 19124372

  • 1. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
    Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K.
    Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S.
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
    Hanania NA, Sethi S, Koltun A, Ward JK, Spanton J, Ng D.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr; 14():117-127. PubMed ID: 30643398
    [Abstract] [Full Text] [Related]

  • 10. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease.
    Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA.
    Pulm Pharmacol Ther; 2007 Aug; 20(5):571-9. PubMed ID: 16911869
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Aug; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 16. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ.
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C.
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.